Topical Vehicle Formulations in the Treatment of Acne

June 2018 | Volume 17 | Issue 6 | Supplement Individual Articles | 6 | Copyright © June 2018

Lauren K. Hoffman BA,a Neal Bhatia MD,b Joshua Zeichner MD,b Leon H. Kircik MDc

aAlbert Einstein College of Medicine, Bronx, NY bMount Sinai Hospital, New York, NY cIcahn School of Medicine at Mount Sinai, NY Indiana School of Medicine, Indianapolis, IN Physicians Skin Care, PLLC, Louisville, KY DermResearch, PLLC, Louisville, KY Skin Sciences, PLLC, Louisville, KY

rates of patient satisfaction. The use of topical antimicrobials and retinoids for treating acne is well established; however, these topical medications are historically known for their local cutaneous irritation, inconvenient dosing, and subsequent poor compliance. Novel formulations that optimize drug concentration and utilize improved delivery vehicles have helped to enhance the tolerability and efficacy, and allow for less frequent application or co-application of drugs that were previously considered incompatible. Combination tretinoin/clindamycin gel and benzoyl peroxide in a hydrophase base are two examples of novel formulations, which have utilized these new technologies and can be used together for the complete treatment of acne. By decreasing irritation and increasing convenience, these novel formulations used together should improve adherence and lead to better therapeutic outcomes as well as decreased antibiotic resistance.


Dr. Hoffman has no conflicts of interest to disclose. Dr. Bhatia is an advisor, consultant, and investigator for Aqua/Almirall. Dr. Zeichner has served as an advisory board member, consultant, or speaker for Abbvie, Allergan, Bayer, Dermira, Galderma, Johnson & Johnson, La Roche Posay, Leo, L'Oreal, Ortho Dermatologics, Pfizer, Promius, Regeneron, Sanofi-Genzyme, Sun Pharma, and Unilever. Dr. Kircik has served as an advisor, investigator, consultant, and speaker for Allergan, Bayer, Galderma, Promius Pharma, Sun Pharma, Stiefel/GSK, LeoPharma, Taro, Valeant, and Warner-Chilcott.


  1. Chourasia R, Jain SK. Drug targeting through pilosebaceous route. Curr Drug Targets. 2009;10(10):950-67.
  2. Wosicka H, Cal K. Targeting to the hair follicles: current status and potential. J Dermatol Sci. 2010;57(2):83-9.
  3. Kircik LH. Importance of vehicles in acne therapy. J Drugs Dermatol. 2011;10(6):s17-23.
  4. Buhse L, Kolinski R, Westenberger B, Wokovich A, Spencer J, Chen CW, et al. Topical drug classification. Int J Pharm. 2005;295(1-2):101-12.
  5. Dreno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448-56.
  6. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1-37.
  7. Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1-50.
  8. Eichenfield LF, Del Rosso JQ, Mancini AJ, Cook-Bolden F, Stein Gold L, Desai S, et al. Evolving perspectives on the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol. 2015;14(3):263-72.
  9. Kircik LH. Re-evaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol. 2014;13(6):s57-60.
  10. Ghali F, Kang S, Leyden J, Shalita AR, Thiboutot DM. Changing the face of acne therapy. Cutis. 2009;83(2 Suppl):4-15.
  11. Weinberg JM. The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris. J Drugs Dermatol. 2006;5(4):344-9.
  12. Kircik LH. The role of benzoyl peroxide in the new treatment paradigm for acne. J Drugs Dermatol. 2013;12(6):s73-6.
  13. Del Rosso JQ. Selection of therapy for acne vulgaris: balancing concerns about antibiotic resistance. Cutis. 2008;82(5 Suppl):12-6.
  14. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology. 2003;206(1):54-6.15.
  15. Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis. 2010;85(1):15-24.
  16. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermatolog Treat. 2002;13(3):107-10.
  17. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117-33.
  18. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol. 2001;15 Suppl 3:43-9.
  19. Brevoxyl Gel US product monograph.
  20. Savoie PWNFJ. An in vitro kill rate study against p. acnes comparing four benzoyl peroxide washes. J Am Acad Dermatol. 2004;50(3):21.
  21. Sawleshwarkar SN, Salgaonkar V, Oberai CM. Multicenter study to evaluate efficacy and irritation potential of benzoyl peroxide 4% cream in hydrophase base (Brevoxyl) in acne vulgaris. Indian J Dermatol Venereol Leprol. 2003;69(1):19-22.
  22. Kircik LH. Harnessing the anti-inflammatory effects of topical dapsone for management of acne. J Drugs Dermatol. 2010;9(6):667-71.
  23. Del Rosso JQ. The role of the vehicle in combination acne therapy. Cutis. 2005;76(2 Suppl):15-8.
  24. Short RWC, J.L.; Choi, J.M.; Egbert, B.M.; Rehmus, W.E.; Kimball, A.B. Effects of moisturization on epidermal homeostasis and differentiation. Clin Exp Dermatol. 2007;32:88-90.
  25. Czernielewski JM, S.; Bouclier, M.; Baker, M.; Hensby, J.C. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):5-12.
  26. Gold LST, J.; Cruz-Santana, A.; Papp, K.; Poulin, Y.; Schlessinger, J.; Gidner, J.; Liu, Y.; Graeber, M. Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110-6.
  27. Gollnick HPD, Z.; Glenn, M.J.; Rosoph, L.A.; Kaszuba, A.; et al. Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris. A transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-9.
  28. Tan JG, H.P.; Loesche, C.; Ma, Y.M.; Gold, L.S. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat [Internet]. 2010.
  29. Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607-15.
  30. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54(1):73-81.
  31. Leyden JJ, Wortzman M. A novel gel formulation of clindamycin phosphate-tretinoin is not associated with acne flaring. Cutis. 2008;82(2):151-6.
  32. Jarratt MT, Brundage T. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study. J Drugs Dermatol. 2012;11(3):318-26.
  33. European Commission Enterprise and Industry Web site [Available from:
  34. Kircik LH, Peredo MI, Bucko AD, Loss RW, Jr., Fowler JF, Jr., Wortzman M, et al. Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study. Cutis. 2008;82(5):358-66.


Leon H. Kircik